Indefinite Delivery Contract 75A50122D00009

This indefinite delivery contract (IDC) was awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a component of the U.S. Department of Health and Human Services (HHS), to Mriglobal, doing business as Midwest Research Institute, a 501(c)(3) not-for-profit research organization. The $45 million single-award IDC has a period of performance through July 31, 2025 and is for the development of animal models to evaluate the efficacy of medical countermeasures (MCMs) against chemical threats, including pulmonary agents, cyanide, opioids, toxic industrial chemicals (TICs), nerve agents, and vesicants.

The original BARDA solicitation sought laboratories capable of conducting controlled animal exposures and establishing models to mimic human disease or conditions from chemical agent exposure. Awardees were required to qualify under either Group A for pulmonary and other chemical threats or Group B for nerve and blister agents, demonstrating prior experience conducting GLP studies. Through this IDC, Mriglobal will provide a range of scientific research, testing, and product development services to support the advancement of MCMs against CBRN threats, as outlined in the Pandemic and All Hazards Preparedness Act. The contract allows ASPR to rapidly issue task orders for Mriglobal's specialized capabilities in areas such as analytical testing, biorepository management, and animal studies.